Skip to main content
LISATA THERAPEUTICS, INC. logo

LISATA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LSTA ISIN · US1280583022 LEI · 5493002287F62M3EGQ04 US Manufacturing
Open in API
Filings indexed 1,093 across all filing types
Latest filing 2018-01-10 Director's Dealing
Country US United States of America
Listing US LSTA

About LISATA THERAPEUTICS, INC.

https://www.lisata.com/

Lisata Therapeutics is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for advanced solid tumors and other major diseases. The company's core technology is the proprietary CendR Platform®, designed to enhance the targeted, tissue-penetrating delivery of anti-cancer drugs to solid tumors. The platform also aims to target non-cancerous, immunosuppressive cells within the tumor microenvironment, seeking to improve the efficacy of a patient's immune system and immunotherapies in fighting cancer.

Recent filings

Filing Released Lang Actions
OWNERSHIP DOCUMENT
Director's Dealing
2018-01-10 English
OWNERSHIP DOCUMENT
Director's Dealing
2018-01-10 English
OWNERSHIP DOCUMENT
Director's Dealing
2018-01-10 English
OWNERSHIP DOCUMENT
Director's Dealing
2018-01-10 English
S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans, such as equity compensation plans. It includes details about the securities to be registered, references to prior filings, and legal indemnification information. It is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length and content confirm it is not a brief announcement or a report publication notice but a full registration statement.
2018-01-04 English
8-K 11.09.17
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 9, 2017, by Caladrius Biosciences, Inc. It reports the issuance of a press release regarding the company's 2017 Third Quarter Financial Results and mentions a conference call to review these results. The document includes a press release as an exhibit but does not contain the full financial statements or detailed financial analysis itself. The document is relatively short (3577 characters) and primarily serves as a current report announcing the release of financial results and related events. This fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights. It is not a full quarterly report (IR) or annual report (10-K), nor is it a regulatory filing of a different nature. Therefore, the appropriate classification is Earnings Release (ER).
2017-11-09 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.